ZVRA — AI Stock Forecast & Price Targets
Published 9/4/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ZVRA price forecast →
ZVRA has quietly transformed into a profitable rare-disease commercial platform: TTM sales +119%, gross margins ~95%, operating margins ~28%, and $145M net cash with debt paid down from $63M to $1.5M. The stock has reclaimed the 20/50/200-day SMAs after a hard June-July drawdown, but sits mid-range ($12.40) with elevated 11% short interest, mixed regulatory overhang (EU arimoclomol), and a forecast model that has been consistently wrong to the downside — argues for accumulating pullbacks rather than chasing.
1-4 weeks: constructive but respect the range. Add on pullbacks to $12.00-12.20 support with a hard invalidation on a daily close below $11.40 (breaks the June structure). Upside target $13.50 then $14.50 into the mid-Sep conference presentations. Size at 1/3 to 1/2 of intended full position given elevated 11% short float can cut both ways and 4h forecast band is bearish. Avoid chasing above $13.30 without a fresh catalyst.
1-6 months: base case is that continued MIPLYFFA revenue scaling and cash build (>$150M by year-end) support a re-rating toward $16-18 as the Nov 4 earnings print likely beats the Street's $0.16 estimate (the crowd itself expects a beat and the trajectory supports it). Key catalysts: (1) Q3 print, (2) any EU arimoclomol re-examination guidance, (3) KP1077 Phase 3 progress commentary. Thesis breaks if EU pathway is definitively closed, Q3 disappoints on MIPLYFFA scripts, or operating margin regresses below 25%.
1-3 years: terminal thesis is that Zevra becomes a mid-cap rare-disease platform with three commercial assets (MIPLYFFA, AZSTARYS, OLPRUVA) plus optionality on KP1077 (IH/narcolepsy) and celiprolol (vEDS). If KP1077 Phase 3 reads out positive, this is a $25-35 stock on SOTP; if it fails, the floor is ~$8-9 backed by the current cash-generative commercial franchise. Structural risk is single-asset dependence — MIPLYFFA is ~half of the ramp and any competitive entrant or reimbursement headwind in NPC would materially impair the story.
The fundamental picture has genuinely inflected. Quarterly revenue has scaled from $26.1M (Q3'25) → $34.1M → $36.2M → $39.7M (Q2'26), a +52% Y/Y trajectory driven by MIPLYFFA uptake in NPC and continued AZSTARYS royalties. Gross margins are ~95-96% (typical of rare-disease specialty pharma), and operating margin printed 42.3% in Q2'26 with $17M of operating cash flow and $16.8M FCF in the quarter alone. The balance sheet is now fortress-like: $145.3M cash vs. only $1.5M debt (down from $63M two quarters ago — the convertible was clearly retired/converted), $217.7M equity, current ratio 5.17. TTM EPS $0.93 gives a trailing P/E of ~13.3 and forward P/E ~11.5 — very cheap for a rare-disease name with 119% TTM sales growth, 33% ROE, and 41% net margins. The only fundamental caveats: PEG of 9.0 reflects that consensus assumes sharp deceleration and negative EPS growth next year (-15.6%), and Q1'26's $37.9M net income was inflated by a one-time item (net margin >100%). Still, cash generation is real and accelerating.
Across timeframes the stock is in a repaired uptrend but stalled near mid-range. The weekly and daily charts show a powerful multi-quarter recovery from the ~$4-7 base area to a July peak near $14.80, followed by a sharp -18% flush to ~$12.20 in early September. Price is now consolidating in the $12.20-12.80 zone, back above the 20-day (+5.25%), 50-day (+2.98%), and 200-day (+20.54%) SMAs — a bullish structural alignment. RSI 58 is neutral-to-positive with room to run. Immediate support is $12.20 (recent flush low) and $11.50 (June breakout); resistance is $13.50 (mid-June congestion) then the $14.50-15.00 supply zone. The 1h chart shows constructive higher-lows since Sep 3. Notably, the model's forecast bands on the 4h/1d/1wk are all deeply bearish ($10.1, $10.06, $6.93), but realized directional accuracy over the last 30 days was 21% (1d) and 17% (1wk) vs. ~80% naive baseline — the model has been systematically wrong on this name, so I discount its bearish print heavily and treat the base-case chart posture as neutral-to-constructive.
Signal: (1) HC Wainwright reiterated Buy with a $26 PT (Aug 20) and Citizens raised to $28 (Aug 6), while Guggenheim trimmed slightly to $23 — consensus target of $25 implies ~100% upside and analyst recom of 1.0 (Strong Buy). (2) The Aug 7 real-world MIPLYFFA/arimoclomol NPC data publication is strategically important as Zevra pursues a re-review path in Europe after the prior negative EMA opinion — this is the single biggest binary catalyst on the horizon. (3) Investor conference presentations at Cantor and Morgan Stanley in early September may draw institutional attention. Noise: routine inducement grants and small insider option exercises. The two insider sells (Chief Legal $475k, Director $138k) are moderate and post-run — not a cluster, not high-conviction bearish, but not encouraging either. Retail sentiment on Stocktwits is 100% bullish which is a mild contrarian caution flag.
- MIPLYFFA (arimoclomol) US commercial ramp in NPC — driving the 52% sequential revenue acceleration and now supported by newly published long-term real-world safety/efficacy data (Aug 7)
- European regulatory path for arimoclomol via re-review after CHMP negative — represents optionality worth several dollars per share if unlocked
- KP1077IH/KP1077N Phase 3 readouts in idiopathic hypersomnia and narcolepsy — a potentially $500M+ TAM expansion
- Celiprolol Phase 3 in vascular Ehlers-Danlos syndrome — another ultra-rare asset with orphan pricing dynamics
- Cash flow inflection: $145M cash and near-zero debt enables tuck-in BD/licensing without dilution, following management's demonstrated capital discipline
- Elevated 11.04% short float + 4.45 days-to-cover means sharp moves in both directions; recent insider selling ($613k combined) offers no conviction offset
- Consensus expects EPS deceleration (-15.6% next Y, PEG 9.0) — if Q3 confirms this, the P/E rerating case weakens
- European arimoclomol pathway remains uncertain; a definitive EU rejection would remove a meaningful piece of the bull thesis
- Sales growth estimate was cut from 201% → 119% (L3 bearish signal Aug 6) — buyside expectations may already be reset lower
- Concentration risk: revenue depends heavily on MIPLYFFA scripts in an ultra-rare indication; script-tracking data misses would hit hard
- The internal forecast model is signaling downside to $6.93-10.11 across timeframes; while its realized accuracy is poor (17-21% vs 80% baseline), the signal cannot be dismissed entirely
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord